New drug combo takes on tough cancers: early trial hopes for better control
NCT ID NCT03257761
First seen Jan 06, 2026 · Last updated Jun 19, 2026 · Updated 31 times
Summary
This early-phase trial is testing a combination of two drugs—guadecitabine and durvalumab—in people with advanced liver, pancreatic, bile duct, or gallbladder cancers that have spread. Guadecitabine aims to block cancer cell growth, while durvalumab helps the immune system attack tumors. The study enrolls 55 participants to find the safest dose and see if the combo can shrink tumors or slow the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
guadecitabine and durvalumab
What this could lead to
If it works, this combination could offer a new treatment option for people with advanced liver, pancreatic, bile duct, or gallbladder cancers.
What could go wrong
This is a very early (phase 1) trial with only 55 participants, so it is mainly checking safety and dosing. The cancers studied are hard to treat, and the combination may not shrink tumors or improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.